Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations

Ortiz and colleagues note that psilocybin-facilitated psychotherapy has accumulating evidence of efficacy across several mental health conditions, yet people from vulnerable populations—defined here as underresourced social groups at elevated risk for poor health outcomes—have been largely underrepresented in clinical psilocybin research. The Introduction situates this gap within broader calls for multicultural competence in mental health care, emphasising the importance of understanding patients' lived experience and provider identity when working with groups such as socioeconomically disadvantaged individuals, people experiencing homelessness, racial/ethnic minorities, sexual and gender minorities (SGM), older adults, people with disabilities or chronic conditions (for example, HIV), and people involved with the criminal justice system. This report, presented as an invited talk at the NIH Psilocybin Research Speaker Series, sets out to provide a concise primer on advancing culturally informed evaluation of psilocybin treatments in vulnerable populations. Rather than exhaustively treating any single group, the authors aim to highlight cross-cutting historical, ethical, methodological, and practical issues and to offer actionable recommendations to improve recruitment, assessment, therapeutic practice, and study design when working with these populations.

The extracted text does not report original empirical methods typical of a clinical trial or systematic review. Instead, the paper is a narrative, perspective-style report based on an invited presentation at the NIH Psilocybin Research Speaker Series. The authors synthesise historical context, prior literature, and experiential and ethical considerations to generate recommendations; they do not describe systematic search procedures, inclusion criteria, or formal data-analytic methods in the extracted text. Because this is a conceptual and practice-focused report rather than a primary dataset analysis, the ‘‘methods’’ consist of thematic exposition: establishing historical precedents, identifying barriers to inclusion, and proposing practical strategies for recruitment, measurement, therapeutic engagement, staff composition, and study logistics. The authors also reference prior empirical and community-based work to support recommendations, but the extraction does not present a formal appraisal or synthesis methodology.

There are no empirical results reported in the extracted text; instead, the authors present a set of findings from the literature and from their synthesis of historical and practical considerations. A central theme is historical context: classic psychedelics have long ritualised uses in some cultures but also a fraught institutional history in the West, including covert and coercive experimentation (for example, CIA involvement and administration to incarcerated people) and exploitative episodes that have undermined trust, notably the case of María Sabina whose sharing of psilocybin ritual knowledge led to harms for her community. These histories help explain current patterns of interest, mistrust, and underrepresentation among some vulnerable groups. The authors identify several practical barriers to including vulnerable populations in psilocybin research. Non-representative recruitment—often relying on convenience samples—tends to favour white, socioeconomically advantaged individuals who have positive expectancies from recent media coverage. Conversely, individuals or communities whose exposure has been limited to sensationalised negative narratives, or who have experienced exploitation by science or disproportionate harm from drug policy, may be difficult to recruit and retain. Cultural objections can also arise where classic psychedelics are sacramental or sacred in origin, and some communities may resist medicalisation or commodification of those practices. Measurement and communication challenges are emphasised. Many self-report instruments used to characterise psilocybin-occasioned experiences (for example, mystical-type scales) were developed in more highly educated samples and lack validation in vulnerable or multilingual populations. The authors recommend using accessible, non-esoteric language to describe likely subjective effects (for example, ‘‘profound awe’’ rather than exclusively ‘‘mystical experience’’) and developing multilingual, culturally sensitive assessment tools. They also advise respecting participants’ religious interpretations rather than dismissing them as merely neurological phenomena. Clinical-process recommendations focus on therapeutic alliance and preparation. Therapeutic alliance—here meaning the working relationship, trust, and rapport between participant and clinicians—should be prioritised because many vulnerable individuals carry histories of powerlessness, adversity, or maltreatment that can amplify distress during psilocybin experiences. The authors note that while a psychological stance of surrender can predict beneficial mystical-type experiences, preoccupation tends to predict challenging experiences; focused preparatory work and empathic support during acute effects are therefore important. The report also expects some participants will struggle during dosing sessions and recommends transparency and empathic response to those challenges. Workforce composition, cultural competence, and structural barriers are also covered. Incorporating scientists and staff from the populations under study may aid recruitment and make procedures more relevant, but the authors caution that representation alone does not guarantee better outcomes. Evidence from other domains shows mixed effects of racial/ethnic or gender matching between clients and therapists on outcomes and retention; by contrast, culturally adapted interventions and higher client ratings of therapist multicultural competence are associated with better process variables and, to a lesser extent, outcomes. The report highlights structural obstacles that limit diversity among investigators and suggests training and entry opportunities across study roles to broaden participation. Finally, practical trial-design adaptations are proposed to reduce participant burden and increase accessibility: flexible scheduling (evenings/weekends), reduced or more efficient session formats where feasible, partial use of mobile technology for psychotherapy and assessment, reasonable noncoercive financial compensation for time and expenses, leniency in rescheduling without penalising enrolment, and reconsideration of overly conservative exclusion criteria that disproportionately disqualify individuals with comorbid medical or psychiatric conditions common in vulnerable populations.

Ortiz and colleagues interpret their synthesis as a call to action: psilocybin-facilitated psychotherapy shows promise, but the field must attend to historical harms, structural barriers, and methodological shortcomings to meaningfully include vulnerable populations. They position their recommendations as preliminary guidance rather than definitive solutions, noting that each vulnerable group warrants more extensive, specific attention than the present broad overview affords. Community engagement is presented as a key mechanism for improving recruitment, retaining participants, and refining study methods and outcomes; the authors cite a pilot example in which community-adapted, psilocybin-facilitated group therapy for demoralisation among gay-identified AIDS survivors was successfully adapted with community input. The authors acknowledge several uncertainties and limits. The evidence base for many of their proposals remains nascent; measures of mystical or subjective experience lack validation in diverse and multilingual samples, and the causal impact of workforce diversity on treatment outcomes is mixed in prior psychotherapy research. They also note practical challenges to diversifying the research workforce, including that involvement in psychedelic research has historically posed career risks and that structural barriers limit access to advanced training for people from marginalised backgrounds. As such, representation is necessary but not sufficient—multicultural competence among clinicians and researchers is emphasised as critical, though how best to define, measure, and improve it is unresolved. In terms of implications, the report advocates for focused, community-partnered recruitment strategies; culturally and linguistically appropriate measurement and communication; prioritising therapeutic alliance and careful preparatory work; pragmatic adaptations to reduce participant burden; thoughtful, noncoercive compensation; and revisiting exclusion criteria that unnecessarily exclude people with common comorbidities. The authors recommend integrating individuals from target populations into research teams across roles and training pathways, while remaining realistic about the barriers and mixed evidence regarding matching or representation effects. Overall, they call for iterative research that refines and expands these ideas so that psilocybin treatment paradigms can be ethically and effectively evaluated in those who bear disproportionate mental health burden.

The paper concludes that while psilocybin-facilitated psychotherapy is a rapidly advancing area with therapeutic potential, vulnerable populations remain a blindspot in clinical research. The authors present this report as an initial overview and offer concrete recommendations—summarised in a table in the original document—to improve representation, measurement, therapeutic practice, and study design. They express hope that future work will refine these recommendations and broaden understanding of how to develop and implement psilocybin treatments for populations that experience disproportionate health burdens.